{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:36:11Z","timestamp":1793298971995,"version":"4.5.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022084","name":"Peter MacCallum Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022084","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euf.2026.06.014","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T03:04:02Z","timestamp":1782615842000},"page":"844-846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radioligand Therapy for Prostate Cancer \u2013 A Clinical Consultation Guide"],"prefix":"10.1016","volume":"12","author":[{"given":"David","family":"Hennes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6234-3522","authenticated-orcid":false,"given":"Abdullah","family":"Al-Khanaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mylestone","family":"Monna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon L.","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu S.","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Buteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7500-5899","authenticated-orcid":false,"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.06.014_b0005","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.06.014_b0010","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2026.06.014_b0015","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2026.06.014_b0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12149-023-01874-5","article-title":"Comparison of PET\/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy","volume":"38","author":"Michalski","year":"2024","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.euf.2026.06.014_b0025","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2967\/jnumed.123.265952","article-title":"SNMMI consensus statement on patient selection and appropriate use of 177Lu-PSMA-617 radionuclide therapy","volume":"64","author":"Hope","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.06.014_b0030","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.3390\/biomedicines12102355","article-title":"Prognostic role of PSMA-targeted imaging in metastatic castration-resistant prostate cancer: an overview","volume":"12","author":"Caracciolo","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.euf.2026.06.014_b0035","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.06.014_b0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5116","article-title":"PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer","volume":"41","author":"Tagawa","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.06.014_b0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","article-title":"Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, Phase 1\/2 study","volume":"85","author":"Eapen","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.06.014_b0050","unstructured":"Chan JC, Carroll MT, Hitchen N, et al. Thrombotic microangiopathy in patients treated with 177Lu-PSMA combination therapies. J Nucl Med 2026;66:jnumed.126.272085."},{"key":"10.1016\/j.euf.2026.06.014_b0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","article-title":"Hematologic safety of 177 Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Groener","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.euf.2026.06.014_b0060","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.2967\/jnumed.124.268363","article-title":"Best Patient Care practices for administering PSMA-targeted radiopharmaceutical therapy","volume":"65","author":"Calais","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.06.014_b0065","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2967\/jnumed.124.268640","article-title":"Therapy-related myeloid neoplasms after [177Lu]Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer: a case series","volume":"66","author":"Eifer","year":"2025","journal-title":"J Nucl Med"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926001100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926001100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:58:40Z","timestamp":1793296720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926001100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2405456926001100"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.06.014","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioligand Therapy for Prostate Cancer \u2013 A Clinical Consultation Guide","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}